Corporate | 22 March 2012 07:30


4SC to host conference call and webcast on 29 March 2012 to present full year financial results


4SC AG / Key word(s): Final Results

22.03.2012 / 07:30


Announcement

4SC to host conference call and webcast on 29 March 2012 to present full year financial results

Planegg-Martinsried, Germany, 22 March 2012 – 4SC AG (Frankfurt, Prime Standard: VSC), a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, will announce its financial results for the year 2011 on 29 March 2012. On this day the Management Board of 4SC AG will host a conference call at 3pm CET (9am EST) to inform about the financial results and important developments in the reporting period.

Participants can access the conference under the following telephone numbers:

Date: 29 March 2012
Time: 3pm CET (9am EST)
Dial-in numbers:
0800 10 12 072 (Germany)
0800 358 2337 (UK)
1 877 941 6013 (USA)
+49 (0) 6958 999 0806 (other countries)
Conference-ID: 4521601

Investors, financial analysts, and journalists participating in the conference call may have live access to the presentation slides at: www.equitystory.com (Login: 4sc0312).

Access to the complete webcast, including presentation slides and voice stream, can be obtained at 3pm CET (9am EST) at: http://4sc290312-live.cyber-presentation.de.

Approximately two hours after the live presentation, an audio replay will be available at the 'investors' section of the homepage www.4sc.com .

Ends

About 4SC AG

4SC (ISIN DE0005753818) discovers and develops targeted small-molecule drugs for the treatment of diseases with a high unmet medical need in various autoimmune and cancer indications. These drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies, and provide a better quality of life. The company's balanced pipeline comprises promising products that are in various stages of clinical development. 4SC's aim is to generate future growth and enhance its enterprise value by entering into partnerships with leading pharmaceutical companies. Founded in 1997, 4SC currently has 94 employees and has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.

Legal Note

This document may contain projections or estimates relating to plans and objectives relating to our future operations, products, or services; future financial results; or assumptions underlying or relating to any such statements; each of which constitutes a forward-looking statement subject to risks and uncertainties, many of which are beyond our control. Actual results could differ materially, depending on a number of factors.

For more information please visit www.4sc.com or contact:

4SC AG
Jochen Orlowski, Investor Relations & Public Relations
jochen.orlowski(at)4sc.com, Tel.: +49 (0) 89 70 07 63 66

Bettina v. Klitzing-Stückle, Corporate Communications
bettina.von.klitzing(at)4sc.com, Tel.: +49 (0) 89 70 07 63 0

MC Services
Raimund Gabriel
raimund.gabriel(at)mc-services.eu , Tel.: +49 (0) 89 21 02 28 30

Mareike Mohr
mareike.mohr(at)mc-services.eu, Tel.: +49 (0) 89 21 02 28 40

The Trout Group (USA)
Chad Rubin
Crubin(at)troutgroup.com, Tel.: +1 646 378 2947



End of Corporate News


22.03.2012 Dissemination of a Corporate News, transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP’s Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language: English
Company: 4SC AG
Am Klopferspitz 19a
82152 Martinsried
Germany
Phone: +49 (0)89 7007 63-0
Fax: +49 (0)89 7007 63-29
E-mail: public@4sc.com
Internet: www.4sc.de
ISIN: DE0005753818
WKN: 575381
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, München, Stuttgart
End of News DGAP News-Service

161605  22.03.2012